# Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)

> **NCT05058105** · PHASE1 · COMPLETED · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** FL058 500mg and Meropenem 1000mg（ IV 120min）
- **DRUG:** FL058 Placebo and Meropenem 1000mg（ IV 120min）
- **DRUG:** FL058 1000mg（ IV 120min）
- **DRUG:** FL058 Placebo （ IV 120min）
- **DRUG:** Meropenem 1000 mg （ IV 120min）
- **DRUG:** Meropenem Placebo （ IV 120min）
- **DRUG:** FL058 1000mg and Meropenem 1000mg （ IV 120min）
- **DRUG:** FL058 Placebo and Meropenem 1000mg （ IV 120min）
- **DRUG:** FL058 1000mg and Meropenem 2000mg （ IV 120min）
- **DRUG:** FL058 Placebo and Meropenem 2000m（ IV 120min）
- **DRUG:** FL058 1000mg and Meropenem 2000mg （ IV 180min）
- **DRUG:** FL058 Placebo and Meropenem 2000m（ IV 180min）
- **DRUG:** FL058 2000mg and Meropenem 2000mg（ IV 180min）
- **DRUG:** FL058 Placebo and Meropenem 2000mg（ IV 180min）

## Key facts

- **NCT ID:** NCT05058105
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-08
- **Primary completion:** 2021-02-24
- **Final completion:** 2021-02-24
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05058105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05058105, "Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05058105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*